PBK/TOPK expression in non-small-cell lung cancer: Its correlation and prognostic significance with Ki67 and p53 expression

Histopathology

Volumn 63, Issue 5, 2013, Pages 696-703

  Lei, Bin ^a,b   Liu, Shuguang ^a,b   Qi, Wenjuan ^a,b   Zhao, Yunfei ^a,b   Li, Yumei ^a,b   Lin, Ni ^a,b   Xu, Xiaoyan ^a,b   Zhi, Chen ^a,b   Mei, Juanjuan ^a,b   Yan, Zhimin ^a,b   Wan, Liyan ^a,b   Shen, Hong ^a,b  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Correlation; Ki67; Non small cell lung cancer; P53; PBK TOPK

Indexed keywords

KI 67 ANTIGEN; PBK PROTEIN; PROTEIN; PROTEIN P53; TOPK PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

CORRELATION; KI67; NON-SMALL-CELL LUNG CANCER; P53; PBK/TOPK;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885426537     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12215     Document Type: Article

References (39)

1. Hofmann HS, Hansen G, Richter G et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin. Cancer Res. 2005; 11; 1086-1092.
2. Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 non-small cell lung cancer. Ann. Thorac. Surg. 2008; 86; 1092-1097.
3. Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J. Biol. Chem. 2000; 275; 21525-21531.
4. Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc. Natl Acad. Sci. USA 2000; 97; 5167-5172.
5. Simons-Evelyn M, Bailey-Dell K, Toretsky JA et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol. Dis. 2001; 27; 825-829.
6. Nandi A, Tidwell M, Karp J, Rapoport AP. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol. Dis. 2004; 32; 240-245.
7. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006; 66; 9186-9195.
8. Herrero-Martin D, Osuna D, Ordonez JL et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br. J. Cancer 2009; 101; 80-90.
9. Zlobec I, Molinari F, Kovac M et al. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br. J. Cancer 2010; 102; 151-161.
10. Zhao S, Dai J, Zhao W et al. PDZ-binding kinase participates in spermatogenesis. Int. J. Biochem. Cell Biol. 2001; 33; 631-636.
11. Dougherty JD, Garcia AD, Nakano I et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J. Neurosci. 2005; 25; 10773-10785.
12. Zykova TA, Zhu F, Vakorina TI et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J. Biol. Chem. 2010; 285; 29138-29146.
13. Abe Y, Takeuchi T, Kagawa-Miki L et al. A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J. Mol. Biol. 2007; 370; 231-245.
14. Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP. PBK/TOPK interacts with the DBD domain of tumour suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 2010; 29; 5464-5474.
15. Zhu F, Zykova TA, Kang BS et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumourigenesis of HCT116 colorectal cancer cells. Gastroenterology 2007; 133; 219-231.
16. Ayllon V, O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 2007; 26; 3451-3461.
17. Shih MC, Chen JY, Wu YC et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012; 31; 2389-2400.
18. Scholzen T, Gerdes J. The Ki-67 protein: from the known and unknown. J. Cell. Physiol. 2000; 182; 311-322.
19. Fei P, El-Deiry WS. p53 and radiation responses. Oncogene 2003; 22; 5774-5783.
20. Driessens G, Harsan L, Browaeys P, Giannakopoulos X, Velu T, Bruyns C. Assessment of in vivo chemotherapy-induced DNA damage in a p53-mutated rat tumour by micronuclei assay. Ann. N. Y. Acad. Sci. 2003; 1010; 775-779.
21. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metast. Rev. 1995; 14; 3-15.
22. Wei DC, Yeh YC, Hung JJ et al. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma. Cancer Sci. 2012; 103; 731-738.
23. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9; 1595-1602.
24. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 2005; 97; 339-346.
25. Le Calvez F, Mukeria A, Hunt JD et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65; 5076-5083.
26. Yamaguchi F, Kugawa S, Tateno H, Kokubu F, Fukuchi K. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer 2012; 78; 201-206.
27. Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumour suppressor p53. Biochem. Biophys. Res. Commun. 2007; 358; 181-188.
28. Kim DJ, Li Y, Reddy K et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 2012; 71; 3060-3068.
29. Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V, Sculier JP. Fragile histidine triad protein expression in non-small cell lung cancer and correlation with Ki-67 and with p53. Eur. Respir. J. 2003; 21; 753-758.
30. Raikhlin NT, Bukaeva IA, Smirnova EA et al. Significance of the expression of nucleolar argyrophilic proteins and antigen Ki-67 in the evaluation of cell proliferative activity and in the prediction of minimal (T1) lung cancer. Arkh. Patol. 2008; 70; 15-18.
31. Werynska B, Pula B, Muszczynska-Bernhard B et al. Correlation between expression of met allothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res. 2011; 31; 2833-2839.
32. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 2000; 102; 323-338.
33. Paik KH, Park YH, Ryoo BY et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J. Korean Med. Sci. 2006; 21; 35-39.
34. Erler BS, Presby MM, Finch M et al. CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumour Biol. 2011; 32; 107-111.
35. Tsubochi H, Sato N, Hiyama M et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in non-small cell lung cancer. Ann. Thorac. Surg. 2006; 82; 1198-1204.
36. Maddau C, Confortini M, Bisanzi S et al. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am. J. Clin. Pathol. 2006; 125; 425-431.
37. Hirai Y, Shimizu Y, Oura S et al. The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer. Gan To Kagaku Ryoho 2012; 39; 381-384.
38. Targowski T, Jahnz-Rozyk K, Owczarek W et al. Telomerase activity and serum levels of p53 protein as prognostic factors of survival in patients with advanced non-small cell lung cancer. Respir. Med. 2010; 104; 1356-1361.
39. Chua HW, Ng D, Choo S et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010; 10; 88-95.